Drug Type Synthetic peptide |
Synonyms pasireotide, PASIREOTIDE PAMOATE, 双羟萘酸帕瑞肽 + [6] |
Mechanism SSTR1 agonists(Somatostatin receptor 1 agonists), SSTR2 agonists(Somatostatin receptor 2 agonists), SSTR3 agonists(Somatostatin receptor 3 agonists) |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (24 Apr 2012), |
RegulationOrphan Drug (US), Priority Review (CN) |
Molecular FormulaC62H73N11O13 |
InChIKeyXOMKXFJQWURETI-KDLQFBCSSA-N |
CAS Registry820232-50-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10497 | Pasireotide Diaspartate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Growth Hormone Excess | JP | 28 Sep 2016 | |
Cushing Syndrome | CN | 27 May 2015 | |
Acromegaly | EU | 24 Apr 2012 | |
Acromegaly | IS | 24 Apr 2012 | |
Acromegaly | LI | 24 Apr 2012 | |
Acromegaly | NO | 24 Apr 2012 | |
Pituitary ACTH Hypersecretion | EU | 24 Apr 2012 | |
Pituitary ACTH Hypersecretion | IS | 24 Apr 2012 | |
Pituitary ACTH Hypersecretion | LI | 24 Apr 2012 | |
Pituitary ACTH Hypersecretion | NO | 24 Apr 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Phase 3 | US | 01 Oct 2009 | |
Pancreatic Fistula | Phase 3 | US | 01 Oct 2009 | |
Malignant Carcinoid Syndrome | Phase 3 | US | 01 Apr 2008 | |
Malignant Carcinoid Syndrome | Phase 3 | AR | 01 Apr 2008 | |
Malignant Carcinoid Syndrome | Phase 3 | AT | 01 Apr 2008 | |
Malignant Carcinoid Syndrome | Phase 3 | BE | 01 Apr 2008 | |
Malignant Carcinoid Syndrome | Phase 3 | BR | 01 Apr 2008 | |
Malignant Carcinoid Syndrome | Phase 3 | CA | 01 Apr 2008 | |
Malignant Carcinoid Syndrome | Phase 3 | FR | 01 Apr 2008 | |
Malignant Carcinoid Syndrome | Phase 3 | DE | 01 Apr 2008 |
Phase 2 | 78 | sflvzaahie(vokbqfjazp) = ffrknvfzoj coybchnqmf (nnwrfmmmqb ) View more | Negative | 25 Jun 2021 | |||
contemporaneous controls | sflvzaahie(vokbqfjazp) = qtqprlgypt coybchnqmf (nnwrfmmmqb ) View more | ||||||
Phase 2 | 19 | lurmsedjbk(qavudfolxt) = awsybzgraq dqaiuhphwk (evxgjtccqs, tmuhxndwfa - oqjdvptjmu) View more | - | 02 Jun 2021 | |||
Phase 2 | 30 | pyupefipfr(lhrwqcskqd) = zxipyfroda uyeaxpcijv (sfqwghvete, dcpdtahjkt - ojmbeostnm) View more | - | 02 Jun 2021 | |||
Phase 2 | 4 | ieeowylhmg(hlbitrvckd) = bvchlhoqwq bxolyxivwo (yphaznmvqy, vysqgczqvx - oflhragxsq) View more | - | 27 Apr 2021 | |||
Phase 2 | 124 | (Pasireotide LAR) | tyzzaggiab(jvhrdtfasc) = btwpgrxtfv yhtoidymbo (clxryzgrqu, wuxkxeuwjm - dptizvovpg) View more | - | 02 Apr 2021 | ||
(Everolimus) | tyzzaggiab(jvhrdtfasc) = tvbjugywnm yhtoidymbo (clxryzgrqu, tuenrhkrxp - rwfjabewko) View more | ||||||
Phase 1/2 | 18 | jxhnbiuzpn(pfeyjmnpgw) = zxfaniludc bpysvregkz (uiuqwixkuj, dwoudqtlui - xdjeeknmgl) View more | - | 25 Mar 2021 | |||
Not Applicable | - | uztupdrnjp(cbhlwiyfxu) = eikojbowgg semeozaeul (gndbavtpgt ) View more | Positive | 22 Sep 2020 | |||
Phase 2 | 68 | cabergoline+Pasireotide | ryykmuvcti(mzehpcabgm) = pjvesoqzjp fsybypinuf (ljsuzvejvf, uearmvikhu - gforgujzrf) View more | - | 18 Sep 2020 | ||
Phase 2 | 48 | vpkktwrmro(syischyxrl) = mkliqaqqvn dcrfexfyeg (vewhuonlxv ) View more | - | 07 Sep 2020 | |||
Placebo | vpkktwrmro(syischyxrl) = drrbcbldxz dcrfexfyeg (vewhuonlxv ) View more | ||||||
Phase 2 | 42 | (Arm A (Everolimus Alone)) | pkdiqmotpn(biitzukzrw) = npexerqptj qezmjzrrbl (cogwdgxdgz, dxeythgbtd - gsvmtwrfch) View more | - | 25 Aug 2020 | ||
(Arm B (Pasireotide Alone)) | pkdiqmotpn(biitzukzrw) = xytcpparey qezmjzrrbl (cogwdgxdgz, idhaftvmfr - pgcjenssfz) View more |